HIF1A and Parkinson disease: Among them, most of the studies are based on the treatment strategies for PD based on the activation of HIF-1α, involving indirect PHD inhibitors, competitive PHD inhibitors, and atypical HIF-1α inducers (Lestón Pinilla et al., 2021).